Lyra Therapeutics (LYRA) to Release Earnings on Tuesday

Lyra Therapeutics (NASDAQ:LYRA) is anticipated to announce its Q1 2025 earnings results before the market opens on Tuesday, April 29th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $0.16 million for the quarter.

Lyra Therapeutics (NASDAQ:LYRA) last announced its earnings results on Thursday, March 13th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.04). The company had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.21 million. Lyra Therapeutics had a negative net margin of 6,635.76% and a negative return on equity of 125.07%. During the same period in the prior year, the business earned ($1.26) earnings per share. On average, analysts expect Lyra Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Lyra Therapeutics Price Performance

Shares of NASDAQ:LYRA opened at $0.09 on Tuesday. Lyra Therapeutics has a one year low of $0.08 and a one year high of $5.65. The company’s fifty day moving average price is $0.15 and its 200-day moving average price is $0.19. The firm has a market capitalization of $5.75 million, a price-to-earnings ratio of -0.06 and a beta of 0.04.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “neutral” rating and set a $2.00 price objective on shares of Lyra Therapeutics in a report on Friday, March 14th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, Lyra Therapeutics currently has a consensus rating of “Hold” and an average price target of $1.25.

About Lyra Therapeutics

Lyra Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.